- OHIO STATE UNIVERSITY -

Led by Professor Pravin Kaumaya

For a full list of publications click here


A paradigm shift Cancer therapy with peptide-based B-cell epitopes and peptideˇimmunotherapeutics targeting multiple solidˇtumor types Eme.png

Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother. 2015;11(6):1368-86.


Prevention of mammaryˇtumors with a chimeric HER-2 B-cell epitope peptide vaccine.png

Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 2000;60(14):3782-9.


Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. Journal of Biological Chemistry.png

Vicari D, Foy KC, Liotta EM, Kaumaya PTP. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. Journal of Biological Chemistry. 2011;286(15):13612-25.


IGF-1R peptide vaccinesmimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and.png

Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PTP. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology. 2014;3(11):e956012.


IGF-1R peptide vaccinesmimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and.png

Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PTP. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology. 2014;3(11):e956005.


Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promis.jpg

Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE, 3rd. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol. 2009;27(31):5270-7.


Peptide vaccines of the HER-2neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.jpg

Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol. 2007;179(1):472-82.


Could precision-engineered peptide epitopesvaccines be the key to a cancer cure.jpg

Kaumaya PT. Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? Future Oncol. 2011;7(7):807-10.


Could precision-engineered peptide epitopesvaccines be the key to a cancer cure.jpg

Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8(8):961-87.


Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.png

Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem. 2011;286(15):13626-37.


- MEDICAL UNIVERSITY OF VIENNA -

Led by Professor Dr Ursula Wiedermann

For a full list of publications click here


Enhanced and long term immunogenicity of a Her-2neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvan.jpg

Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer. 2017 Feb 9;17(1):118. doi: 10.1186/s12885-017-3098-7


A virosomal formulated Her-2neu multi-peptide vaccine induces Her-2neu-specific immune responses in patients with metastatic breast cancer.jpg

Wiedermann U and C.C. Zielinski. Vaccination for prevention and treatment of breast cancer. Breast Cancer Res Treat. 2013 Feb;138(1):1-12


A virosomal formulated Her-2neu multi-peptide vaccine induces Her-2neu-specific immune responses in patients with metastatic breast cancer.jpg

Wiedermann U, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer. R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner, C.C. Zielinski. 2010. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 119 (3):673-83.


Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen–Positive Tumors in BALBc Mice.png

Wagner S, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder. 2008. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res.;14(24):8178-83.


A virosomal formulated Her-2neu multi-peptide vaccine induces Her-2neu-specific immune responses in patients with metastatic breast cancer.jpg

Wagner, S.; J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. 2007 Jan 3; 106(1):29-38.


Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen–Positive Tumors in BALBc Mice.png

Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res. 2007 Nov 1;13(21):6501-8.


Active induction of tumor-specific IgE antibodies by oral mimotope vaccination.jpg

Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007 Apr 1;67(7):3406-11.


Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific mo.png

Hafner, C.; H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer, 114:426.


Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti–Epidermal Growth Factor Receptor Antibodies.png

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.


Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2neu.png

Jasinska J, WagnerS, RadauerC, SedivyR, BrodowiczT, WiltschkeC, Breiteneder H, Pehamberger H, Scheiner O, WiedermannU*, Zielinski CC. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int. J. Cancer. 2003. 20; 107:976-83.